D-27 | Clinical Efficacy of Sotagliflozin in Cardiovascular Outcomes: An Analysis of SCORED and SOLOIST-WHF Clinical Trials

Sotagliflozin (SF), an inhibitor of both sodium-glucose cotransporter 1 and 2 (SGLT1-2), is a recently approved drug against heart failure (HF). Our study highlights the efficacy of SF in cardiovascular (CV) outcomes in patients with HF. We conducted a systemic literature search in PubMed and EMBASE up to December 19, 2023, using MeSH terms "sotagliflozin" and "heart failure". The risk ratio (RR) of urgent visits for HF, hospitalization, and mortality, along with a 95% confidence interval (CI) and P-values, were extracted using RevMan v.5.4. Out of total screened 11826 patients, 11806 patients were enrolled for analysis from SCORED, SOLOIST-WHF clinical trials. A total of 5900 patients were enrolled in SF group (A), and 5906 were enrolled in placebo group, with an average follow-up of 12.5 months. Urgent visits and hospitalization for HF was 7.4% in group A as compared to group B (11.1%) with RR:0.67 (CI: 0.60-0.74, p<0.05). Mortality from CV causes in group A was 3.5% as compared to group B (3.9%), with RR:0.91 (CI: 0.75-1.09, p=0.29). Mortality from CV causes, hospitalizations, and urgent visits for HF in group A was 10.9% as compared to group B (15%) with RR:0.72 (CI: 0.66-0.79, p<0.05). Mortality from CV causes, hospitalization for HF, nonfatal myocardial infarction and strokes in group A was 13.3% compared with B group (18%) with RR:0.74 (CI: 0.69-0.80, p< 0.05). Diarrhea and hypotension were more common in group A than in group B. Sotagliflozin showed promising results in terms of risk reduction in urgent visits for HF, hospitalizations, and death from CV causes, providing a benchmark for future studies.